IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by NBT Bank N A NY

NBT Bank N A NY lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4,583.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 562 shares of the company’s stock after purchasing an additional 550 shares during the quarter. NBT Bank N A NY’s holdings in IDEXX Laboratories were worth $232,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. FSA Wealth Management LLC purchased a new position in shares of IDEXX Laboratories during the third quarter worth $25,000. Rialto Wealth Management LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter worth $30,000. Ashton Thomas Securities LLC purchased a new position in shares of IDEXX Laboratories during the third quarter worth $37,000. Retirement Wealth Solutions LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter worth $31,000. Finally, Kestra Investment Management LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter worth $38,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 2.2 %

IDXX stock opened at $426.69 on Wednesday. The stock has a market capitalization of $34.70 billion, a P/E ratio of 39.99, a P/E/G ratio of 3.41 and a beta of 1.39. The firm has a 50-day simple moving average of $438.11 and a 200-day simple moving average of $448.27. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $552.20.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on IDXX. Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Piper Sandler lifted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners began coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective for the company. Finally, Barclays lifted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average price target of $533.75.

Insider Transactions at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.18% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.